Biogen Inc (NASDAQ:BIIB) CMO Alfred Sandrock sold 1,981 shares of the stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $274.08, for a total value of $542,952.48. Following the transaction, the chief marketing officer now directly owns 7,060 shares of the company’s stock, valued at approximately $1,935,004.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Biogen Inc (NASDAQ:BIIB) traded up 0.18% during mid-day trading on Friday, reaching $272.94. The company’s stock had a trading volume of 1,125,629 shares. The stock has a market capitalization of $58.94 billion, a P/E ratio of 16.12 and a beta of 0.72. Biogen Inc has a 1-year low of $223.02 and a 1-year high of $333.65. The stock’s 50 day moving average price is $278.72 and its 200 day moving average price is $287.90.
Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, January 26th. The biotechnology company reported $5.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.96 by $0.08. Biogen had a net margin of 32.34% and a return on equity of 38.48%. The firm earned $2.87 billion during the quarter, compared to the consensus estimate of $2.94 billion. During the same period last year, the firm posted $4.50 EPS. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Analysts expect that Biogen Inc will post $20.96 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/04/21/insider-selling-biogen-inc-biib-cmo-sells-542952-48-in-stock-updated.html.
Institutional investors have recently made changes to their positions in the stock. Freestone Capital Holdings LLC purchased a new position in shares of Biogen during the fourth quarter valued at about $659,000. Capital Guardian Trust Co. increased its position in shares of Biogen by 130.1% in the fourth quarter. Capital Guardian Trust Co. now owns 359 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 203 shares in the last quarter. Harvest Fund Management Co. Ltd purchased a new position in shares of Biogen during the fourth quarter valued at about $110,000. Thompson Siegel & Walmsley LLC increased its position in shares of Biogen by 3.0% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 408 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. Finally, Capital Analysts LLC increased its position in shares of Biogen by 1.4% in the fourth quarter. Capital Analysts LLC now owns 423 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 6 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts recently commented on the company. Credit Suisse Group AG reaffirmed a “neutral” rating and issued a $312.00 price target on shares of Biogen in a report on Friday, December 30th. Robert W. Baird reaffirmed a “hold” rating on shares of Biogen in a report on Tuesday, February 7th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $313.00 price target on shares of Biogen in a report on Tuesday, January 24th. Leerink Swann cut Biogen from an “outperform” rating to a “market perform” rating and set a $300.00 price target for the company. in a report on Thursday, March 16th. Finally, Cantor Fitzgerald set a $293.00 price target on Biogen and gave the company a “hold” rating in a report on Thursday, January 26th. Twelve analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $326.64.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.